



7 June 2022

**Hemogenyx Pharmaceuticals plc**

("Hemogenyx" or the "Company")

LEI 2138008L93GYU5GN6179

**Posting of Annual Report & Notice of Annual General Meeting**

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2021, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy were posted to shareholders today and are available on the Company's website at <https://hemogenyx.com/investors/annual-and-half-year-reports>, and the 2021 Equity Incentive Plan with Non-Employee Sub-Plan (relating to AGM Resolution 5) is available on the Company's website at <https://hemogenyx.com/investors/company-profile/company-information>.

The AGM is to be held on 30 June 2022 at 2.00 pm BST at the offices Shakespeare Martineau LLP, 60 Gracechurch Street, London EC3V 0HR.

**Enquiries:**

**Hemogenyx Pharmaceuticals plc**

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Peter Redmond, Director

<https://hemogenyx.com>

[headquarters@hemogenyx.com](mailto:headquarters@hemogenyx.com)

[peter.redmond@hemogenyx.com](mailto:peter.redmond@hemogenyx.com)

**SP Angel Corporate Finance LLP**

Matthew Johnson, Vadim Alexandre, Adam Cowl

Tel: +44 (0)20 3470 0470

**Peterhouse Capital Limited**

Lucy Williams, Duncan Vasey, Charles Goodfellow

Tel: +44 (0)20 7469 0930